Overview: NGS Charcot-Marie-Tooth Sequencing TestIntroduction: The NGS Charcot-Marie-Tooth Sequencing Test sequences genes to diagnose Charcot-Marie-Tooth disease (CMT), causing nerve damage or muscle weakness. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected CMT.
Other Names: CMT Assay, PMP22/GJB1 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: CMT sequencing began in the 1990s with neuropathy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose CMT, guides treatment, and evaluates patients with nerve damage or muscle weakness.
Test Parameters: 1. CMT Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of nerve damage, muscle weakness, or CMT symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document nerve damage, muscle weakness, foot deformities, or family history of CMT. Include current medications, especially pain relievers.
Consent: Written consent required, detailing the tests purpose, CMT implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze CMT genes (e.g., PMP22, GJB1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for CMT diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm CMT, guiding supportive care or genetic counseling. Negative results may require nerve conduction studies.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Nerve conduction studies, EMG, or nerve biopsy to confirm CMT diagnosis.
Test Limitations: Not all CMT cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN CMT Guidelines, 2023; Neurology, Reilly MM, 2022.
